Diverticular Disease Market 2023 Top Key Players are Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Synergy Pharmaceuticals

Market Research Future has added a report titled “Diverticular Disease Market Research Report - Forecast to 2023” to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.

Global Diverticular disease market is expected to grow at a CAGR of 7.5% during the forecast period.

Market Scenario:

Diverticular disease is a digestive condition that leads to the formation of sacs or small bulges in the wall of the large intestine. These sacs can be formed anywhere in the colon, but it is majorly found in the sigmoid colon. Diverticular disease can be caused by many factors such as low fiber diet, lack of physical exercise, and certain medications like anti-inflammatory drugs, lack of vitamin D, obesity, and smoking.

The global diverticular disease market is majorly driven by growing prevalence of obesity, rising older population leading to rise in patient population, the rise in cigarette smoking population, and growing mass young population inclined towards a sedentary lifestyle. Additionally, factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market.

According to the United Nations, in 2017 approximately over 962 million population were aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This rising aging population is likely to propel the growth of global Diverticular disease market. Factors that are likely to hamper the growth of the market are the complications that will arise after the needed treatment.

Get Premium Copy @ https://www.marketresearchfuture.com/sample_request/5694

Key Players

Diverticular disease market Top Key Players are Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Synergy Pharmaceuticals, Inc. Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.

D.C. Description: diverticula, small bulges, large intestine, colon , fistulas, diet low , Americas Diverticular Disease market, Asia Pacific Diverticular Disease market.

Segments

The global Diverticular disease market is segmented on the basis of type, treatment, diagnosis and end user.

On the basis of the type, the market is segmented into diverticulosis, diverticulitis and diverticular bleeding.

On the basis of treatment, the market is segmented into medications, supportive care, and surgery. Medication segment is further divided into antibiotics, a penicillin antibiotic, and dietary supplements. Supportive care segment is further classified into IV fluids.

On the basis of diagnosis, the market is segmented into barium X-ray, CT scan, liver function test, stool test, blood test, ultrasound, urine test, and others.

On the basis of the end user, the market is segmented into specialty centers, hospitals, and research centers.

Regional Analysis

North America Diverticular disease market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of passive smokers, along with rising older population is likely to drive the market. Additionally, growing healthcare expenditure and rising demand for technologically advanced treatment and products along with rising government support is likely to enhance the growth of Diverticular disease market in North America.

Europe is the second largest market and holds a healthy share in the global Diverticular disease market. The European market is expected to grow at a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and rising skilled medical professionals along with growing need for better healthcare infrastructure. Furthermore, rising older population, along with growing inclination towards sedentary lifestyle are driving the growth of Diverticular disease market.

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases is the major driver for the market growth. China is the fastest growing region owing to an increasingly older population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and rise in the standard of living are driving the growth of Diverticular disease market in the Asia Pacific region.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.

Table Of Content

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5 Market Factor Analysis

…Continued!

Browse Full Reports @ https://www.marketresearchfuture.com/reports/diverticular-disease-market-5694

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.